Amy Mimi Lin, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Amy Mimi Lin, MD

Assistant Clinical Professor, Department of Medicine, UCSF

Phone: (415) 476-4616 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

View on UCSF Profiles

Education

Harvard University, Cambridge, MA, AB, 1989-1993, Biology
UCLA School of Medicine, Los Angeles, CA, 1994-1996
University of Chicago, Pritzker School of Medicine, Chicago, IL MD, 1996-1999, Medicine
New York Presbyterian Hospital-Cornell, New York, NY, Internship/ residency, 1999-2002, Internal Medicine
University of California, San Francisco, San Francisco, CA, Fellowship, 2002-2005, Medicine (Hematology Oncology)
University of California, San Francisco, San Francisco, CA, Fellowship, 2005-2006, Medicine (Urologic Oncology)


Professional Experience

  • 2006-2008
    Clinical Instructor of Medicine, Division of Hematology Oncology, UCSF
  • 2006-present
    Staff physician, San Francisco Veterans Administration Medical Center (SF VAMC), Medicine (Hematology/Oncology
  • 2008-present
    Assistant Clinical Professor, Medicine, UCSF

Honors & Awards

  • 1990-1991
    Harvard College Scholarship for Academic Excellence (Harvard University)
  • 1991-1992, 1990-1991
    Elizabeth Agassiz Award for Academic Excellence (Harvard University)
  • 1991-1992
    John Harvard Scholarship for Academic Excellence (Harvard University
  • 1993
    Magna cum laude in Field of Biology (Harvard University)
  • 1994
    Dr. Ursula Mandel Scholarship (UCLA School of Medicine)
  • 1995
    Short-Term Training Program (STTP) grant (UCLA School of Medicine)
  • 1998-1999
    Calvin Fentress Research Fellowship Award, University of Chicago
  • 2004
    American Association of Clinical Research (AACR)/American Society of Clinical Oncology (ASCO) Methods in Clinical Cancer Research Workshop
  • 2005
    ASCO Multi-disciplinary Prostate Cancer Symposium Merit award
  • 2005-2006
    ASCO Young Investigator Award
  • 2007-2008
    Cancer and Leukemia Group B (CALGB) Foundation Young Investigator Award

Selected Publications

  • Peer-reviewed publications
  • Bastos R, A Lin, M Enarson, B Burke. "Targeting and function in mRNA export of nuclear pore complex protein Nup153" Journal of Cell Biology 1996, 134(5):1141-1156
  • Wu MH, SL Smith, GH Danet, AM Lin, SF Williams, DN Liebowitz, ME Dolan. "Optimization conditions to enhance transfection of human CD34+ cells by electroporation" Bone Marrow Transplantation 2001, 27: 1201-1209
  • Lin AM, BI Rini, EJ Small. "Clinical trials in biochemically relapsed prostate cancer patients" BJU International 2006, 97(5):905-10.
  • Lin AM, BI Rini, V Weinberg, K Fong, CJ Ryan, JE Rosenberg, L Fong, EJ Small. "A phase II trial of imatinib mesylate in prostate cancer patients with biochemical relapse following definitive local therapy" BJU International 2006, Oct; 98(4):763-9.
  • Lin, AM, CJ Ryan, EJ Small. "Intermittent chemotherapy for metastatic hormone-refractory prostate cancer" Critical Reviews in Oncology and Hematology 2007 Mar ;61(3):243-54.
  • Lin, AM, BI Rini, M Kakefuda, V Weinberg, M Randall, CJ Ryan, JE Rosenberg, G Bubley, EJ Small. "A phase I trial of estramustine, docetaxel, and imatinib mesylate in hormone refractory prostate cancer patients" Clinical Genitourinary Cancer 2007 Jun; 5(5):323-8.
  • Ryan, CJ, AH Harzstark, J Rosenberg, A Lin, C Claros, ID Goldfine, JF KErner, EJ Small. "A pilot dose-escalation study of the effects of nordihydroguaracetic acid in hormone and prostate specific antigen levels in patients with relapsed prostate cancer" BJU International 2008, 101(4):436-9.
  • Ryan, CJ, V Weinberg, J Rosenberg, L Fong, A Lin, J Kim, EJ Small. "Phase II study of ketoconazole plus granulocyte-macrophage stimulating factor for prostate cancer: effect of extent of disease on outcome" J Urology 2007, Dec; 178(6):2372-6..
  • Non-peer reviewed publications:
  • "Screening tests for cancer: prostate cancer" The Medical Letter September 2005, 3(37):63-68
  • Lin AM, RM Hershberg, EJ Small. "Immunotherapy for prostate cancer using prostatic acid phosphatase (PAP) loaded antigen presenting cells" Urologic Oncology 2006 Sep-Oct;24(5):434-41.
  • Lin, AM, EJ Small, CJ Ryan. "A phase II trial of ketoconazole plus granulocyte macrophage-colony stimulating factor (GM-CSF) for androgen independent prostate cancer (AIPC)" Clinical Advances in Hematology and Oncology 2006, 4(4):16-19 (Supplement 9).
  • Ryan, CJ, AM Lin, EJ Small. "Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer" Urologic Oncology 2006, 24(3):250-3.
  • Lin, AM, EJ Small. "Prostate cancer update 2006" Current Opinion in Oncology 2007, 19(3): 229-233.
  • Lin, AM, EJ Small. "Asymptomatic hormone refractory prostate cancer" In press US Kidney and Urologic Disease 2007
  • Lin, AM, EJ Small. "Management of hormone refractory prostate cancer" In press Current Opinion in Supportive and Palliative Care 2007
  • Lin, AM, EJ Small. "Prostate cancer update 2007" Current Opinion in Oncology 2008, 20(3):294-9.
  • ABSTRACTS:
  • Wu MH, DN Liebowitz, KE Mikolajczak, AM Lin, SL Smith, SF Williams, ME Dolan. "Selective protection of bone marrow cells from alkylating agent toxicity" ISHAGE 1998 (poster presentation)
  • Wu, MH, DN Liebowitz, KE Mikolajczak, AM Lin, ME Dolan. "Sensitivity of mutant O6-alkylguanine-DNA alkyl transferases (AGT) to O6-benzylguanine (BG) and O6-benzyl-8-oxoguanine" Proceedings of the American Association of Cancer Research 1998, 39:517
  • Smith, SL, AM Lin, GH Danet, KE Mikolajczak, J Ng-Cashin, SF Williams, ME Dolan, DN Liebowitz. "Expansion of CD34 bright cells using Flt-3 ligand, stem-cell factor and thrombopoietin" ISHAGE 1998 (poster presentation)
  • Lin A, M Randall, B Rini, C Ryan, J Rosenberg, J Garcia, G Bubley, E Small. "The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer patients: results of a phase I trial" Proceedings of American Society of Clinical Oncology 2004, 23:409, abstract #4617 (selected for poster presentation)
  • Lin AM, K Fong, V Weinberg, BI Rini, CJ Ryan, J Rosenberg, L Fong, C Haqq, EJ Small. "A phase II trial of imatinib mesylate in prostate cancer patients with biochemical relapse (BCR) after definitive local therapy" American Society of Clinical Oncology Multi-disciplinary Prostate Cancer Symposium 2005, abstract #258 (selected for poster presentation)
  • Lin AM, CJ Ryan, J Rosenberg, BI Rini, T Nguyen, V Weinberg, EJ Small. "A phase II trial of ketoconazole plus granulocyte macrophage-colony stimulating factor (GM-CSF) for androgen independent prostate cancer (AIPC)" American Society of Clinical Oncology 2005, abstract #4614 (selected for poster presentation)
  • Lin AM, CJ Ryan, J Rosenberg, BI Rini, T Nguyen, V Weinberg, EJ Small. "A phase II trial of ketoconazole plus granulocyte macrophage-colony stimulating factor (GM-CSF) for androgen independent prostate cancer (AIPC)" American Society of Clinical Oncology Multi-disciplinary Prostate Cancer Symposium 2006, abstract #219 (selected for poster presentation)
  • Lin, AM, JE Rosenberg, VK Weinberg, WK Kelly, MD Michaelson, M Hussain, G Wilding, ME Gross, EJ Small. "Clinical outcome of taxane-resistant hormone refractory prostate cancer patients treated with subsequent chemotherapy (ixabepilone or mitoxantrone/ prednisone)" Proceedings of the American Society of Oncology 2006, Part I. Vol 24, No. 18S (June 20 Supplement), abstract #4558 (selected for poster discussion)
  • Ryan, CJ, J Rosenberg, A Lin, L Ruttner, V Weinberg, E Small. "Outcome of patients with non-metastatic versus metastatic hormone refractory prostate cancer (HRPC) treated with second-line hormonal therapy consisting of ketoconazole (keto) plus granulocyte macrophage colony stimulating factor (GM-CSF)" Proceedings of the American Society of Clinical Oncology 2006, Part I. Vol 24, No. 18S (June 20 Supplement), abstract #4626 (selected for poster presentation)
  • Ryan, CJ, J Rosenberg, A Lin, J Valiente, J Kim, EJ Small. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). Proceedings of the American Society of Clinical Oncology 2007, Part I. Vol 25, No. 18S (June 20 Supplement), abstract #5064